Board of Directors

  • Beth Seidenberg, M.D. — Kleiner Perkins Caufield & Byers (KPCB)

    Beth joined Kleiner Perkins Caufield & Byers in May 2005 to work in the life sciences area. Beth was formerly the Senior Vice President, Global Development, and Chief Medical Officer at Amgen. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb and Merck & Co. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. In total, she introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis. She is currently on the Board of Directors of 3-V Biosciences, Arresto Biosciences, BioCryst Pharmaceuticals, Breathe Technologies, Epizyme, iPierian, Inc, and RedBrick Health. Her primary focus is in novel therapeutics to treat unmet medical needs.

    Beth received her B.S. from Barnard College and her medical degree from the University Of Miami School Of Medicine. Her post-graduate training was completed at Johns Hopkins and the National Institutes of Health.

  • Mark Gudiksen, Ph.D — TPG Biotech

    Prior to joining TPG Biotech in 2008, Mark Gudiksen was an Engagement Manager in McKinsey & Company’s west coast healthcare practice. At McKinsey, he worked on a broad spectrum of strategic topics and M&A opportunities with a variety of clients, including biopharmaceutical & medical device companies, hospital chains, and private equity firms. In addition to serving on the Board of Directors of Auxogyn, Inc., Mark is also a board observer for Nodality, Inc.

    Mark received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford. Mark’s doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal.

  • Simeon George, M.D. — SR One

    Simeon George joined SR One in 2007 and leads SR One’s investment activities on the West Coast. Prior to joining SR One, Simeon was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.  Simeon is a member of the Board of Directors of Anaphore, Auxogyn, Inc., Genocea Biosciences, HTG Molecular, Principia Biosciences and Semprus BioSciences.

    Simeon received his B.A. in Neuroscience from the Johns Hopkins University, where he graduated Phi Beta Kappa. Simeon received his MD from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania.

  • Hakan Goker, P.h.D — Merck Serono Ventures

    Hakan Goker (Ph.D.) is a senior director at MS Ventures, the corporate venture capital fund of Merck Serono. Hakan joined MS Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan has been instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Orphazyme (DK), F Star (NL), Bicycle Therapeutics (UK), Nimbus Discovery (US) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in oncology from the Institute of Cancer Research/ University of London and continued his scientific career at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Forendo Pharma, Synaffix, Asceneuron, Raze Therapeutics, Tocopherx, and Progyny Inc.